GO:0048147 negative regulation of fibroblast proliferation: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048147 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of fibroblast multiplication.
• Fibroblast proliferation is a central driver of fibrosis, wound healing, and tumor stroma remodeling, making its negative regulation a key therapeutic node.
• Multiple signaling pathways converge to restrain fibroblast proliferation, including TGF-beta/Smad7, PI3K/AKT/mTOR, YAP-TEAD/RUNX2, integrin/FAK, and FGFR-dependent cascades.
• Smad7 induction in fibroblasts protects the pressure-overloaded heart by limiting fibroblast proliferation and remodeling.
• Triptolide reduces epidural fibrosis by negatively regulating the PI3K/AKT/mTOR axis, which suppresses fibroblast proliferation and induces apoptosis and autophagy.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to causally test which genes truly brake fibroblast proliferation.
Description
Fibroblasts are the principal matrix-producing cells of connective tissue and are essential for wound repair, but their uncontrolled proliferation underlies fibrosis, organ failure, and tumor-promoting stroma. The Gene Ontology term GO:0048147, negative regulation of fibroblast proliferation, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of fibroblast multiplication. Understanding this term is critical because restoring the brakes on fibroblast proliferation is a validated therapeutic strategy in cardiac, hepatic, dermal, and epidural fibrotic disease. Mechanistically, negative regulation of fibroblast proliferation is not a single pathway but an integrated network of cytokine, kinase, and transcription-factor signals that converge on cell-cycle entry, survival, and autophagic flux. For example, fibroblast Smad7 induction protects the remodeling pressure-overloaded heart by attenuating proliferative signaling, while combined YAP-TEAD and YAP-RUNX2 signaling integrates substrate stiffness to control cardiac fibroblast proliferation. In parallel, autophagic degradation of SQSTM1 enables fibroblast activation, showing that catabolic programs can either restrain or license proliferation depending on context. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0048147, its key genes, disease relevance, and the CRISPR-based methods used to study it.
negative regulation of fibroblast proliferation At A Glance
| GO ID | GO:0048147 |
|---|---|
| GO term | negative regulation of fibroblast proliferation |
| Ontology | biological_process |
| Synonym | down regulation of fibroblast proliferation; down-regulation of fibroblast proliferation; downregulation of fibroblast proliferation; inhibition of fibroblast proliferation |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of fibroblast multiplication or reproduction |
| Biological context | Fibrosis resolution, wound healing restraint, tumor stroma remodeling, cardiac and hepatic protection |
| Key signaling axes | TGF-beta/Smad7, PI3K/AKT/mTOR, YAP-TEAD/RUNX2, integrin/FAK, FGFR, autophagy |
| Representative genes | SMAD7, PTEN, YAP1, RUNX2, SQSTM1, FGFR1, ITGB1, AKT1, MTOR |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, imaging, functional proliferation assays |
What Is GO:0048147?
GO:0048147, negative regulation of fibroblast proliferation, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of multiplication or reproduction of fibroblast cells. In practical terms, it encompasses signaling events, transcriptional programs, and metabolic or autophagic changes that keep fibroblast division in check. Synonyms include down regulation of fibroblast proliferation, down-regulation of fibroblast proliferation, downregulation of fibroblast proliferation, and inhibition of fibroblast proliferation. The term is a biological_process child of the broader regulation of fibroblast proliferation and is distinct from positive regulation of fibroblast proliferation, which promotes the same cellular outcome.
Why Is negative regulation of fibroblast proliferation Important in Cell Biology?
Negative regulation of fibroblast proliferation is important because fibroblasts are the central effector cells of fibrosis, and their unchecked expansion drives scarring and organ dysfunction in the heart, liver, skin, and epidural space. At the same time, fibroblast proliferation is required for normal wound healing, so the negative regulation arm must be finely tuned rather than simply silenced. The term therefore sits at the intersection of regenerative biology and fibrotic disease, and it is a high-value target for therapeutic intervention.
• Restrains pathological fibrosis in the pressure-overloaded heart through fibroblast Smad7 induction.
• Limits epidural fibrosis by downregulating PI3K/AKT/mTOR signaling in fibroblasts.
• Controls skin fibrosis by suppressing integrin/FAK, p-AKT/p-ERK, and TGF-beta cascades.
• Modulates cancer-associated fibroblast behavior and T cell infiltration in triple-negative breast cancer.
• Balances fibroblast activation and wound healing through autophagic degradation of SQSTM1.
• Integrates mechanical cues via YAP-TEAD and YAP-RUNX2 signaling in cardiac fibroblasts.
• Provides a mechanistic counterweight to fibroblast activation protein-driven inflammation and fibrosis in the liver.
• Offers a conceptual framework for designing anti-fibrotic therapies that spare normal repair.
• Enables causal gene discovery when combined with CRISPR knockout and overexpression screens.
• Supports biomarker and target validation in fibrotic and stromal-rich tumors.
What Happens During negative regulation of fibroblast proliferation?
Initiation: sensing pro-proliferative and anti-proliferative cues
In simple terms: The cell first decides whether to divide by weighing growth signals against stop signals.
Negative regulation of fibroblast proliferation begins with the integration of extracellular and mechanical cues. In cardiac fibroblasts, substrate stiffness is sensed and transduced through combined YAP-TEAD and YAP-RUNX2 signaling, which determines whether proliferation proceeds or is restrained. In fibrotic skin, integrin/FAK and TGF-beta signaling provide pro-proliferative input that must be counteracted by negative regulators such as miR-3606-3p. In the liver, fibroblast activation protein activates macrophages and promotes parenchymal inflammation and fibrosis, illustrating how stromal cross-talk can override intrinsic brakes on fibroblast proliferation.
Signal transduction: kinase and transcription-factor brakes
In simple terms: Inside the cell, specific kinase and transcription-factor circuits act as brakes on division.
A central brake is the PI3K/AKT/mTOR axis: negative regulation of this axis reduces fibroblast proliferation and simultaneously modulates apoptosis and autophagy, as shown in triptolide-induced reduction of epidural fibrosis. TGF-beta signaling is another key node, where fibroblast Smad7 induction protects the remodeling pressure-overloaded heart by attenuating proliferative remodeling. YAP-TEAD and YAP-RUNX2 signaling further integrate stiffness-dependent inputs to control cardiac fibroblast proliferation. These pathways converge on cell-cycle entry and survival decisions, and their coordinated restraint defines the negative regulation arm of fibroblast proliferation.
Autophagy and catabolic control
In simple terms: Autophagy, the cell's recycling system, can either support or restrain fibroblast activation depending on context.
Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing, demonstrating that autophagy is not uniformly anti-proliferative but is context-dependent. In epidural fibrosis, negative regulation of PI3K/AKT/mTOR is accompanied by changes in autophagy, linking catabolic flux to reduced fibroblast proliferation. This dual role means that the negative regulation of fibroblast proliferation must be interpreted together with autophagic status rather than in isolation.
Outcome: reduced fibroblast number and matrix deposition
In simple terms: When the brakes work, there are fewer dividing fibroblasts and less scar tissue.
The functional outcome of GO:0048147 is a reduced frequency, rate, or extent of fibroblast multiplication, which translates into decreased extracellular matrix deposition and attenuated fibrosis. In the pressure-overloaded heart, Smad7 induction in fibroblasts protects against adverse remodeling. In epidural fibrosis, negative regulation of PI3K/AKT/mTOR reduces fibroblast proliferation and fibrosis. In skin fibrosis, integrated suppression of integrin/FAK, p-AKT/p-ERK, and TGF-beta cascades alleviates fibrotic pathology. In tumors, FGFR blockade regulates cancer-associated fibroblasts and boosts T cell infiltration, showing that restraining fibroblast proliferation can remodel the tumor microenvironment.
Systems-level stability and circuit design
In simple terms: Stable control of fibroblast number depends on the design of the signaling circuit, not just one molecule.
Circuit design features of a stable two-cell system illustrate how negative regulation can maintain stable cell numbers through feedback and coupling between cell types. This systems perspective is relevant to fibroblast proliferation because stromal and immune cells exchange signals that determine whether fibroblasts expand or remain quiescent. Fibroblast activation protein-driven macrophage activation and liver inflammation exemplify how intercellular circuits can promote fibrosis when negative regulation fails. Thus, GO:0048147 should be viewed as a network property emerging from multiple cell types and pathways.
Key Genes Involved in GO:0048147 negative regulation of fibroblast proliferation
The following genes and proteins have been experimentally implicated in the negative regulation of fibroblast proliferation or in the signaling circuits that control it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD7 | Induced in fibroblasts to protect the pressure-overloaded heart by attenuating proliferative remodeling | Cardiac fibrosis target; KO and overexpression models test causality |
| PTEN | Negative regulator of PI3K/AKT/mTOR signaling | Central brake on fibroblast proliferation; loss-of-function promotes fibrosis |
| AKT1 | Kinase in the PI3K/AKT/mTOR axis whose negative regulation reduces fibroblast proliferation | Drug and CRISPR perturbation studies in epidural fibrosis |
| MTOR | Kinase node integrating growth signals; its negative regulation suppresses fibroblast proliferation | Target of triptolide and rapamycin-like interventions |
| YAP1 | Transcriptional co-activator integrating substrate stiffness with TEAD and RUNX2 | Mechanotransduction studies in cardiac fibroblasts |
| RUNX2 | Transcription factor partnering with YAP to control stiffness-dependent fibroblast proliferation | Combined YAP-TEAD and YAP-RUNX2 signaling models |
| SQSTM1 | Autophagy receptor whose degradation enables fibroblast activation and wound healing | Context-dependent role in proliferation and autophagy |
| FGFR1 | Receptor tyrosine kinase whose blockade regulates cancer-associated fibroblasts | Tumor stroma remodeling and T cell infiltration studies |
| ITGB1 | Integrin subunit feeding into FAK signaling in skin fibrosis | Target of miR-3606-3p-mediated suppression |
| FAK (PTK2) | Focal adhesion kinase downstream of integrins | Integrin/FAK cascade in skin fibrosis |
| FAP | Fibroblast activation protein that activates macrophages and promotes liver fibrosis | Stromal-immune cross-talk and liver fibrosis models |
| TGFB1 | Master cytokine driving fibroblast activation and proliferation | Counteracted by Smad7 and miR-3606-3p |
| MIR3606 | MicroRNA that integratively suppresses integrin/FAK, p-AKT/p-ERK, and TGF-beta cascades | Anti-fibrotic miRNA therapy candidate |
| ERK1/2 (MAPK3/MAPK1) | Kinases in the p-ERK arm suppressed during negative regulation of fibroblast proliferation | Readout of anti-proliferative signaling |
| CDKN1A (p21) | Cyclin-dependent kinase inhibitor mediating cell-cycle arrest | Downstream effector of anti-proliferative signals |
| TP53 | Tumor suppressor coordinating cell-cycle arrest and apoptosis | Context-dependent brake in fibroblast proliferation |
| BECN1 | Autophagy regulator linked to fibroblast catabolic control | Autophagy-proliferation interplay studies |
| COL1A1 | Major extracellular matrix output reduced when fibroblast proliferation is restrained | Fibrosis endpoint measurement |
How Is negative regulation of fibroblast proliferation Regulated?
Negative regulation of fibroblast proliferation is controlled by layered signaling. The PI3K/AKT/mTOR axis is a central regulatory node: its negative regulation reduces fibroblast proliferation and modulates apoptosis and autophagy, as demonstrated in triptolide-induced epidural fibrosis reduction. TGF-beta signaling is counterbalanced by Smad7 induction in fibroblasts, which protects the pressure-overloaded heart. Mechanical inputs are integrated by YAP-TEAD and YAP-RUNX2 signaling, linking substrate stiffness to cardiac fibroblast proliferation. Integrin/FAK and p-AKT/p-ERK cascades are suppressed by miR-3606-3p in skin fibrosis. Autophagic degradation of SQSTM1 adds another regulatory layer that can enable fibroblast activation and wound healing. Finally, intercellular circuits involving fibroblast activation protein and macrophages can override intrinsic brakes and promote liver inflammation and fibrosis.
negative regulation of fibroblast proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD7 | Pressure-overload cardiac fibrosis | Fibroblast-specific Smad7 knockout and overexpression in mouse heart |
| PTEN / AKT1 / MTOR | Epidural fibrosis | Triptolide-treated fibroblast cultures and epidural fibrosis models |
| MIR3606 | Skin fibrosis | miR-3606-3p mimic/inhibitor in dermal fibroblasts and skin fibrosis models |
| FAP | Liver inflammation and fibrosis | FAP knockout or inhibition in liver fibrosis models |
| FGFR1 | Triple-negative breast cancer stroma | FGFR blockade in cancer-associated fibroblast co-culture and tumor models |
Cardiac fibrosis and pressure-overload remodeling
In the pressure-overloaded heart, fibroblast Smad7 induction protects against adverse remodeling by restraining fibroblast proliferation and matrix deposition. Combined YAP-TEAD and YAP-RUNX2 signaling integrates substrate stiffness to control cardiac fibroblast proliferation, linking mechanotransduction to fibrotic disease. These findings position GO:0048147 as a protective program in the heart and a target for anti-fibrotic therapy.
Epidural fibrosis
Triptolide reduces epidural fibrosis by negatively regulating the PI3K/AKT/mTOR axis, which suppresses fibroblast proliferation and modulates apoptosis and autophagy. This demonstrates that pharmacological activation of the negative regulation arm can limit post-surgical scarring.
Skin fibrosis
miR-3606-3p alleviates skin fibrosis by integratively suppressing the integrin/FAK, p-AKT/p-ERK, and TGF-beta signaling cascades, thereby restraining fibroblast proliferation and matrix production. This highlights miRNA-based strategies to reinforce negative regulation of fibroblast proliferation.
Liver fibrosis and tumor stroma
Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis, showing how stromal-immune circuits can overcome negative regulation of fibroblast proliferation. In triple-negative breast cancer, FGFR blockade regulates cancer-associated fibroblasts and boosts T cell infiltration, indicating that restraining fibroblast proliferation can remodel the tumor microenvironment.
From negative regulation of fibroblast proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is SMAD7 causally protective against cardiac fibroblast proliferation? | Fibroblast-specific SMAD7 knockout and knock-in mouse models |
| Does negative regulation of PI3K/AKT/mTOR reduce epidural fibrosis? | PTEN overexpression or AKT1/MTOR point-mutation models in fibroblasts |
| How does substrate stiffness control fibroblast proliferation? | YAP1 and RUNX2 knockout or point-mutation in cardiac fibroblasts on tunable substrates |
| Does SQSTM1 degradation license fibroblast activation? | SQSTM1 knockout and tagged knock-in autophagy reporter fibroblasts |
| Can miRNA restore brakes on skin fibrosis? | miR-3606-3p overexpression and target-site knock-in in dermal fibroblasts |
| Does FGFR blockade remodel tumor stroma? | FGFR1 knockout or point-mutation in cancer-associated fibroblasts |
How to Study the negative regulation of fibroblast proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and proliferation rate | Quantifying negative regulation of fibroblast proliferation |
| Ki-67 immunofluorescence | Fraction of cycling cells | Validating anti-proliferative interventions |
| RNA-seq | Transcriptional changes in signaling networks | Identifying brakes such as SMAD7 and PTEN |
| Proteomics / phosphoproteomics | Protein abundance and kinase activity | Mapping PI3K/AKT/mTOR and FAK/ERK changes |
| Immunofluorescence imaging | Subcellular localization of YAP1 and autophagy markers | Mechanotransduction and autophagy studies |
| Co-culture assays | Intercellular signaling effects on fibroblast proliferation | Macrophage-fibroblast and tumor-stroma models |
| Substrate-stiffness assays | Mechanical control of proliferation | Cardiac fibroblast mechanobiology |
| Circuit modeling | Stability and feedback in two-cell systems | Systems-level interpretation of proliferation control |
Functional proliferation assays
EdU/BrdU incorporation, Ki-67 staining, and live-cell growth curves are standard readouts for the frequency and rate of fibroblast multiplication. These assays are used to quantify the outcome of negative regulation of fibroblast proliferation after genetic or pharmacological perturbation.
Transcriptomic and proteomic profiling
RNA-seq and proteomics identify the signaling networks that restrain fibroblast proliferation, including PI3K/AKT/mTOR, TGF-beta/Smad7, and integrin/FAK components. Differential expression of COL1A1 and cell-cycle genes provides functional context.
Imaging and mechanotransduction assays
Immunofluorescence for YAP1 localization and traction-force or substrate-stiffness assays reveal how mechanical cues are integrated into proliferation decisions in cardiac fibroblasts. Live imaging of autophagy reporters can simultaneously track SQSTM1 flux.
Co-culture and systems-level modeling
Co-culture of fibroblasts with macrophages or cancer cells, combined with circuit-design modeling, captures how intercellular signaling overrides or reinforces negative regulation of fibroblast proliferation.
How CRISPR Can Be Used to Study GO:0048147 negative regulation of fibroblast proliferation
Knockout
CRISPR knockout of candidate brakes such as SMAD7, PTEN, or SQSTM1 tests whether loss of function accelerates fibroblast proliferation and fibrosis. Knockout models are essential for establishing causality in GO:0048147.
Point Mutation
Point mutations in kinase domains or phospho-sites of AKT1, MTOR, or FAK can dissect which catalytic activities are required for negative regulation of fibroblast proliferation. Such models distinguish scaffolding from enzymatic functions.
Knock-in
Knock-in of reporters or disease-relevant variants, such as tagged SQSTM1 or mutant YAP1, enables precise tracking of autophagy flux and mechanotransduction in living fibroblasts.
Overexpression
Overexpression of SMAD7, PTEN, or miR-3606-3p reinforces the negative regulation arm and tests whether boosting brakes is sufficient to reduce fibrosis in cardiac, epidural, and skin models.
How EDITGENE Supports negative regulation of fibroblast proliferation Research
Researchers studying negative regulation of fibroblast proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining fibroblast multiplication or is merely correlated with a fibrotic phenotype. Rigorous causal inference requires isogenic cell models in which the candidate gene is knocked out, point-mutated, knocked in, or overexpressed, followed by quantitative proliferation and matrix assays. EDITGENE provides these models at scale to accelerate target validation in GO:0048147 research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of fibroblast proliferation research.
Frequently Asked Questions About negative regulation of fibroblast proliferation
What is GO:0048147 negative regulation of fibroblast proliferation?
GO:0048147 is a Gene Ontology biological_process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of multiplication or reproduction of fibroblast cells.
What genes are involved in negative regulation of fibroblast proliferation?
Key genes include SMAD7, PTEN, AKT1, MTOR, YAP1, RUNX2, SQSTM1, FGFR1, ITGB1, FAK, FAP, and MIR3606, based on published fibrosis and mechanotransduction studies.
How does Smad7 protect the pressure-overloaded heart?
Fibroblast Smad7 induction protects the remodeling pressure-overloaded heart by attenuating proliferative remodeling and fibrosis.
Does negative regulation of PI3K/AKT/mTOR reduce epidural fibrosis?
Yes, triptolide reduces epidural fibrosis by negatively regulating the PI3K/AKT/mTOR axis, which suppresses fibroblast proliferation and modulates apoptosis and autophagy.
What is the role of YAP-TEAD and YAP-RUNX2 in fibroblast proliferation?
Combined YAP-TEAD and YAP-RUNX2 signaling mediates substrate-stiffness regulation of cardiac fibroblast proliferation.
How does autophagy affect fibroblast activation?
Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing, showing context-dependent effects on proliferation.
Can miRNA restore negative regulation of fibroblast proliferation in skin fibrosis?
miR-3606-3p alleviates skin fibrosis by integratively suppressing integrin/FAK, p-AKT/p-ERK, and TGF-beta signaling cascades.
How is fibroblast activation protein linked to liver fibrosis?
Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis.
Does FGFR blockade affect cancer-associated fibroblasts?
FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
What CRISPR models are used to study negative regulation of fibroblast proliferation?
Knockout, point-mutation, knock-in, and overexpression models in fibroblasts are used to test causal roles of genes such as SMAD7, PTEN, SQSTM1, and YAP1.
Conclusion
GO:0048147, negative regulation of fibroblast proliferation, is a biologically and clinically important process that restrains fibroblast expansion in fibrosis, wound healing, and tumor stroma. Published literature identifies multiple converging brakes, including TGF-beta/Smad7, PI3K/AKT/mTOR, YAP-TEAD/RUNX2, integrin/FAK, and autophagy-related pathways. Because these pathways are context-dependent and interconnected, causal gene discovery requires rigorous CRISPR-based models combined with quantitative proliferation and matrix assays. EDITGENE provides the knockout, point-mutation, knock-in, overexpression, and screening platforms needed to advance this research toward anti-fibrotic therapeutics.
References
- 1. Zhou X et al.. 2018. Circuit Design Features of a Stable Two-Cell System.. Cell 172(4):744-757.e17 PMID: 29398113
- 2. Humeres C et al.. 2024. Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart.. Circ Res 135(3):453-469 PMID: 38899461
- 3. Dai J et al.. 2019. Negative regulation of PI3K/AKT/mTOR axis regulates fibroblast proliferation, apoptosis and autophagy play a vital role in triptolide-induced epidural fibrosis reduction.. Eur J Pharmacol 864:172724 PMID: 31600493
- 4. Yang AT et al.. 2023. Fibroblast Activation Protein Activates Macrophages and Promotes Parenchymal Liver Inflammation and Fibrosis.. Cell Mol Gastroenterol Hepatol 15(4):841-867 PMID: 36521660
- 5. Xu Y et al.. 2025. Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing.. Autophagy 21(11):2401-2421 PMID: 40400126
- 6. Ebrahimighaei R et al.. 2022. Combined role for YAP-TEAD and YAP-RUNX2 signalling in substrate-stiffness regulation of cardiac fibroblast proliferation.. Biochim Biophys Acta Mol Cell Res 1869(11):119329 PMID: 35905788
- 7. Chen Y et al.. 2025. miR-3606-3p alleviates skin fibrosis by integratively suppressing the integrin/FAK, p-AKT/p-ERK, and TGF-β signaling cascades.. J Adv Res 75:271-290 PMID: 39571732
- 8. Wu Y et al.. 2022. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.. Theranostics 12(10):4564-4580 PMID: 35832090
